Becton, Dickinson and Company (BD) is in a transformative period in its development. The medication delivery to lab tests and biosciences research company has been reinventing itself and its approach to the evolving medtech market in the past decade. The die was cast when the now 127-year-old company bought CareFusion Corporation in 2015 and then in 2017 followed it with another major transaction, the purchase of C.R. Bard.
Those acquisitions helped BD to almost triple its revenues in the following years
Key Takeaways
-
The balance of BD’s business is being shifted more in favor of selected high-growth segments under the company’s 2025 strategy.
-
AI and connected care applications are being applied to BD’s “durable core” business – which still accounts for three quarters of revenues
